Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03578302 · ClinicalTrials.gov registry record
The Heidelberg Engineering BI US Evaluation Study
A clinical trial, sponsored by Heidelberg Engineering.
- Completed
- Registry status
- 39
- Enrollment target
NCT03578302: Completed study, sponsored by Heidelberg Engineering.
NCT03578302 is a clinical trial that has completed, run by Heidelberg Engineering. The registered enrollment target is 39 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03578302 has completed, sponsored by Heidelberg Engineering.
- COMPLETED
- Registry status
- 39 participants
- Enrollment target
Study Summary
Evaluation of defined parameters measured in pathological and non-pathological eyes with the Heidelberg BI
Primary Outcome
Percentage of successfully scanned biometry images of the eyes per scan mode. Success is defined as agreement of the subjective assessment of the operator and the auto assessment of the device.
Interventions
- DEVICE BI Anterior Segment Mode
- DEVICE BI Anterior Segment and IOL Biometry Mode
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2018-05-22 |
| Est. Completion | 2018-12-03 |
What the finished NCT03578302 record still lists
NCT03578302 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 39 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which BI Anterior Segment Mode is the first listed.
NCT03578302 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03578302 about?
NCT03578302 is a clinical study titled "The Heidelberg Engineering BI US Evaluation Study". Evaluation of defined parameters measured in pathological and non-pathological eyes with the Heidelberg BI
What is the current status of trial NCT03578302?
This trial is currently completed. The enrollment target is 39 participants. The study started on 2018-05-22. Estimated completion is 2018-12-03.
What interventions are being tested in trial NCT03578302?
The interventions under investigation include: BI Anterior Segment Mode (DEVICE), BI Anterior Segment and IOL Biometry Mode (DEVICE).
Who is sponsoring clinical trial NCT03578302?
This trial is sponsored by Heidelberg Engineering, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI